Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.370 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
leukemia
|
0.090 |
Biomarker
|
disease |
BEFREE |
These findings implicate the JNK pathway in transformation by a human leukemia oncogene.
|
8524841 |
1995 |
Childhood Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
These findings implicate the JNK pathway in transformation by a human leukemia oncogene.
|
8524841 |
1995 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells.
|
9115218 |
1997 |
Small cell carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
The findings suggest that UV-stimulated JNK1 activation promotes UV-induced SCLC apoptosis, while a JNK isoform that is variably activated among the SCLC lines may signal a UV-protective response.
|
9092556 |
1997 |
Amyotrophic Lateral Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We show that (a) the JNK/SAPK-c-Jun pathway is dramatically overexpressed in ALS spinal cord; (b) the strongest activation occurs in astrocytes, while motor neurons show unusually low expression of the pathway; (c) increased JNK/SAPK expression in glial cells is accompanied by NF-kappa B activation, indicating the presence of a protective response to oxidant sress, which is deficient in motor neurons; (d) activation of JNK/SAPK, c-Jun and NF-kappa B is unrelated to apoptotic cell death.
|
9413280 |
1997 |
Hypoglycemia
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells.
|
9115218 |
1997 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of JNK-1, ERK-1, p38/RK and MKP-1 proteins was investigated by immunohistochemistry and expression of MKP-1 mRNA by in situ hybridisation in 50 cases of high-grade prostatic intraepithelial neoplasia (PIN), thought to represent the precursor of prostate cancer.
|
9645439 |
1998 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of JNK-1, ERK-1, p38/RK and MKP-1 proteins was investigated by immunohistochemistry and expression of MKP-1 mRNA by in situ hybridisation in 50 cases of high-grade prostatic intraepithelial neoplasia (PIN), thought to represent the precursor of prostate cancer.
|
9645439 |
1998 |
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, bFGF production by KS and HUVEC is dependent on the activation of the ERK and JNK cascades, which result in the transcriptional activation of the bFGF promoter.
|
9456251 |
1998 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have previously found that epidermal growth factor (EGF) mediates growth through the Jun N-terminal kinase/stress-activated kinase (JNK/SAPK) pathway in A549 human lung carcinoma cells.
|
10022881 |
1999 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1. tBHQ and SUL also activated MAPK kinase.
|
10488090 |
1999 |
Carcinoma, Ovarian Epithelial
|
0.040 |
Biomarker
|
disease |
BEFREE |
We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.
|
10353733 |
1999 |
Liver neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1. tBHQ and SUL also activated MAPK kinase.
|
10488090 |
1999 |
Multiple Sclerosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In active MS lesions, double-label immunohistochemistry with oligodendrocyte markers showed up-regulation of the nuclear staining for both NF-kappaB and JNK on a large proportion of oligodendrocytes located at the edge of active lesions and on microglia/macrophages throughout plaques.
|
10550297 |
1999 |
Fibrosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
|
10086335 |
1999 |
Adult Fibrosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
|
10086335 |
1999 |
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.
|
10353733 |
1999 |
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the response of the mitogen-activated protein kinases, extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun-N-terminal kinase 1 (JNK1), and p38, to cisplatin treatment in the ovarian carcinoma cell line SK-OV-3.
|
10353733 |
1999 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the current study, we examined the role of JNK- and ERK-dependent signaling modules in the regulation of MMP-9 production and the invasive behavior of the human glioblastoma cell line SNB19, in which JNK/ERK1 is constitutively activated.
|
11315098 |
2000 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, the influence of JNK on basal (unstimulated) growth of human tumor glioblastoma T98G cells was investigated using highly specific JNK antisense oligonucleotides to inhibit JNK expression.
|
10825181 |
2000 |
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
RGD |
Inhibition of JNK-1 activation might become an innovative means of therapy for stroke treatment in the future.
|
10773432 |
2000 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that the constitutive activation of ERK1/2, JNK1 and p38 is not a feature of colorectal cancers.
|
10769637 |
2000 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we examined the role of JNK- and ERK-dependent signaling modules in the regulation of MMP-9 production and the invasive behavior of the human glioblastoma cell line SNB19, in which JNK/ERK1 is constitutively activated.
|
11315098 |
2000 |